Skip to content

Investors / Press Releases


The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.


Filter Releases
 
Press Releases
Date Title and Summary View
May 18, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, May 18, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today three new studies it is coordinating with leading health organizations and physicians. These stu...
May 3, 2017
Prescription Growth Up >50%; Outcomes Study Beyond 80% Complete Re-affirms Guidance on Full Year Net Product Revenues of between $155 and $165 Million Management to Host Conference Call at 8:00 a.m. ET Today BEDMINSTER, N.J. and DUBLIN, Ireland, May 03, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical com...
Apr 25, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, April 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the c...
Mar 21, 2017
NEW YORK, BEDMINSTER, N.J., and DUBLIN, Ireland, March 21, 2017 (GLOBE NEWSWIRE) -- The American Heart Association and American Stroke Association announced today that John Thero will serve as chairman of its annual Heart & Stroke Ball scheduled for June 14, 2017 in New York City. The American Heart Association and American Stroke Association's ...
Mar 16, 2017
Mar 15, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, March 15, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced the publication today of the rationale and design for the company's REDUCE-IT Phase 3 cardiovascular outcomes study in Clinical Cardiology, available at: http://onlinelibrary.wiley.com/doi/10.1002/clc.22692/full. Deepak L. Bh...
Feb 28, 2017
$130.1 Million and $38.7 Million Total Revenue for Full Year and Fourth Quarter 2016 Reflect Increases of 59% and 45% Compared to Corresponding Periods in 2015  REDUCE-IT Cardiovascular Outcomes Study Remains on Schedule to Reach Onset of Final Target Event Near the End of 2017Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, ...
Feb 22, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the co...
Feb 9, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the company will participate in the Leerink Partners 6th Annual Global Healthcare Conferen...
Jan 20, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) ("Amarin") announced today that it and its wholly owned subsidiary, Corsicanto II Designated Activity Company (the "Issuer"), have entered into separate, privately negotiated purchase agreements with certain investors pursuant to which the...
Jan 5, 2017
Unaudited Full-Year 2016 Net Product Revenue Estimated to Modestly Exceed Upper End of $112 to $125 Million Previously Guided Range Anticipate Full-Year 2017 Net Product Revenues Between $155 Million and $165 Million; Commercial Operations Positioned to be Cash Flow Positive for 2017 BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 05, 2017 (GLOB...
Dec 16, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (the "Company") announced today that it is providing a contractual reminder to holders of the outstanding 3.50% Exchangeable Senior Notes due 2032 (CUSIP Number: 220480 AC1) (the "Notes") of its wholly owned subsidiary, Corsicanto Designat...
Nov 14, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced an oral presentation at the American Heart Association Scientific Sessions 2016, New Orleans on November 14, 2016 that further characterized the efficacy and safety of Vascepa® (icosapent ethyl) in statin-treated women...
Nov 11, 2016
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a ...
Nov 3, 2016
Third Quarter Net Product Revenue Up 52% vs. Prior Year Period Maintaining Guidance on 2016 Net Product Revenue at $112-$125 Million;Anticipate Upper Half of RangeManagement to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceu...
Page:
...
Next Last
 
= add release to Briefcase